A retrospective study evaluating clinical outcomes of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jun 2017 New trial record
- 06 Jun 2017 Primary endpoint (Overall survival (OS)) has been met.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology